Nursing Elites

1. Which type of heart disease involves the stiffening of the heart muscle, reducing its ability to relax and fill with blood?

• A. Restrictive cardiomyopathy
• B. Hypertrophic cardiomyopathy
• C. Dilated cardiomyopathy
• D. Ventricular hypertrophy

Correct answer: A

Rationale: The correct answer is A, restrictive cardiomyopathy. This condition specifically involves the stiffening of the heart muscle, leading to a reduced ability to relax and fill with blood between beats. Choice B, hypertrophic cardiomyopathy, is characterized by abnormal thickening of the heart muscle, not stiffening. Choice C, dilated cardiomyopathy, involves the enlargement and weakening of the heart chambers, not stiffening. Choice D, ventricular hypertrophy, refers to the thickening of the walls of the heart's pumping chambers but does not specifically involve the stiffening that is characteristic of restrictive cardiomyopathy.

2. What is a condition where the heart is unable to relax properly between beats, reducing its ability to fill with blood?

• A. Diastolic heart failure
• B. Systolic heart failure
• C. Hypertrophic cardiomyopathy
• D. Restrictive cardiomyopathy

Correct answer: A

Rationale: The correct answer is A: Diastolic heart failure. In diastolic heart failure, the heart is unable to relax properly between beats, leading to a reduced ability to fill with blood. This condition primarily affects the heart's filling function rather than its pumping function, which is characteristic of systolic heart failure (choice B). Hypertrophic cardiomyopathy (choice C) involves the abnormal thickening of the heart muscle, while restrictive cardiomyopathy (choice D) is characterized by the heart muscle becoming stiff and less compliant. Therefore, choices B, C, and D are incorrect in the context of a heart condition where relaxation between beats is impaired.

3. A client on spironolactone (Aldactone) has a potassium level of 6.0 mEq/L. What is the nurse’s priority action?

• A. Hold the spironolactone and notify the healthcare provider.
• B. Administer a potassium supplement.
• C. Continue the spironolactone as ordered.
• D. Increase the dose of spironolactone.

Correct answer: A

Rationale: The correct action for a client on spironolactone with a potassium level of 6.0 mEq/L is to hold the medication and notify the healthcare provider. Spironolactone is a potassium-sparing diuretic that can further elevate potassium levels, which are already high. Administering a potassium supplement (Choice B) would exacerbate the hyperkalemia. Continuing the spironolactone as ordered (Choice C) could lead to worsening hyperkalemia. Increasing the dose of spironolactone (Choice D) would be contraindicated in the presence of elevated potassium levels.

4. Which valve prevents backflow of blood into the right ventricle from the pulmonary artery?

• A. Pulmonary valve
• B. Aortic valve
• C. Tricuspid valve
• D. Mitral valve

Correct answer: A

Rationale: The correct answer is the Pulmonary valve. The Pulmonary valve prevents backflow of blood into the right ventricle from the pulmonary artery after it has been ejected. The Aortic valve (choice B) prevents backflow from the aorta into the left ventricle. The Tricuspid valve (choice C) prevents backflow of blood into the right atrium from the right ventricle. The Mitral valve (choice D) prevents backflow from the left ventricle into the left atrium.

5. For what reason might the nurse be given an order to administer milrinone (Primacor)?

• A. For congestive heart failure
• B. For hypertension
• C. For cardiac arrhythmias
• D. For bradycardia

Correct answer: A

Rationale: Milrinone is commonly prescribed for congestive heart failure to help improve cardiac function and alleviate symptoms. Choices B, C, and D are incorrect as milrinone is not typically used for hypertension, cardiac arrhythmias, or bradycardia. It is specifically indicated for congestive heart failure for short-term management.

Similar Questions